Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

PAQ Therapeutics Closes $30 Million Round for Autophagy-Caused Degredation

publication date: Jul 15, 2021

PAQ Therapeutics, a Cambridge, Mass. autophagy company, closed a $30 million Series A round from China investors. The company develops novel small molecule autophagosome-tethering compounds (ATTECs) designed to catalyze autophagy-dependent degradation of disease-causing substrates. PAQ's initial target is Huntington's Disease. The A round was led by Sherpa Healthcare Partners with Huagai Capital, MSA Capital, and MRL Ventures Fund participating, joined by seed investors, Nest.Bio Ventures and Matrix Partners China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital